Objective
The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations.
MultipleMS will therefore develop, validate, and exploit methods for patient stratification in Multiple Sclerosis, a chronic inflammatory disease and a leading causes of non-traumatic disability in young adults, with an estimated cost of €37 000 per patient per year over a duration of 30 years. Here we benefit from several large clinical cohorts with multiple data types, including genetic and lifestyle information. This in combination with publically available multi-omics maps enables us to identify biomarkers of the clinical course and the response to existing therapies in a real-world setting, and to gain in-depth knowledge of distinct pathogenic pathways setting the stage for development of new interventions.
To create strategic global synergies, MultipleMS includes 21 partners and covers not only the necessary clinical, biological, and computational expertise, but also includes six industry partners ensuring dissemination and exploitation of the methods and clinical decision support system. Moreover, the pharmaceutical industry partners provide expertise to ensure optimal selection and validation of clinically relevant biomarkers and new targets. Our conceptual personalized approach can readily be adapted to other immune-mediated diseases with a complex gene-lifestyle background and broad clinical spectrum with heterogeneity in treatment response.
MultipleMS therefore goes significantly beyond current state-of-the-art thereby broadly affecting European policies, healthcare systems, innovation in translating big data and basic research into evidence-based personalized clinical applications.
Fields of science
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health scienceshealth sciencespersonalized medicine
Keywords
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
17177 Stockholm
Sweden
See on map
Participants (23)
13128 Stockholm
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
171 77 Stockholm
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
00014 Helsingin Yliopisto
See on map
02130 Espoo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
0313 Oslo
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
0450 Oslo
See on map
3400 Hillerod
See on map
81675 Muenchen
See on map
3000 Leuven
See on map
WC1E 6BT London
See on map
CB21 6GH Cambridge
See on map
CB2 1TN Cambridge
See on map
69117 Heidelberg
See on map
1205 Geneve
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08036 Barcelona
See on map
20132 Milano
See on map
13100 Vercelli
See on map
98121 Seattle
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
100 44 Stockholm
See on map
91380 Chilly Mazarin
See on map
94607 Oakland Ca
See on map
Participation ended
20097 San Donato Mi
20122 Milano
See on map